Drug overpricing: Govt plans amnesty scheme to recover dues from pharma companies

In a bid to tackle overpricing in the pharmaceutical sector, the government is planning an amnesty scheme to recover dues from pharmaceutical companies, CNBC Aawaz reported.

The National Pharmaceutical Pricing Authority (NPPA), responsible for overseeing drug pricing, has identified a substantial 2,200 cases of overpricing within the pharmaceutical industry.

Among the companies under scrutiny for overpricing practices are well-known names such as Cipla, Sun Pharma, and Lupin. These cases collectively involve dues amounting to approximately Rs. 13,000 crore.

The amnesty scheme proposes relief for pharmaceutical companies, offering waivers on interest and penalties associated with the alleged overpricing issues.

Pharma makers get a year for GMP implementation, Mandaviya warns action on defaults

The primary objective of the amnesty scheme is to recover outstanding dues from these companies. It is estimated that the government aims to retrieve around Rs. 5,000 to 6,000 crore through this initiative.

How are drug prices regulated?

Periodically, the Health Ministry collaborates with experts to create the National List of Essential Medicines (NLEM). This list includes medications vital for treating prevalent conditions and falls under price control through the Drug Price Control Order (DPCO).

The NPPA, a part of the Indian Government, was established to regulate drug prices. It enforces pricing and availability of medicines as per the Drugs (Prices Control) Order, 1995. NPPA also recovers overcharged amounts from consumers and monitors prices of unregulated drugs to ensure affordability.

Related Posts

  • Pharma
  • October 17, 2024
  • 116 views
CSIR-NIIST To Establish Centres Of Excellence In Ayurveda, Performance Chemicals

Thiruvananthapuram:  The Centre of Excellence in Ayurveda Research to be established on the campus of the CSIR-National Institute for Interdisciplinary Science and Technology (NIIST) at Pappanamcode here is envisaged as…

  • Pharma
  • October 17, 2024
  • 104 views
India, Uzbekistan Discuss Ways To Ensure Quality, Safety In Pharma Sector

New Delhi:  A delegation from Uzbekistan met officials from India’s Central Drugs Standard Control Organisation and discussed areas of collaboration, including the development of a pharmacovigilance system and reducing adverse…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

CSIR-NIIST To Establish Centres Of Excellence In Ayurveda, Performance Chemicals

CSIR-NIIST To Establish Centres Of Excellence In Ayurveda, Performance Chemicals

India, Uzbekistan Discuss Ways To Ensure Quality, Safety In Pharma Sector

India, Uzbekistan Discuss Ways To Ensure Quality, Safety In Pharma Sector

Health Worker Arrested For Mixing TB Patient’s Sputum In Doctor’s Food

Health Worker Arrested For Mixing TB Patient’s Sputum In Doctor’s Food

Cipla, Alkem Eye Rs 4,000 Crore Stake In India’s Largest Stent Manufacturer

Cipla, Alkem Eye Rs 4,000 Crore Stake In India’s Largest Stent Manufacturer

DTAB Recommends To Do Away With Toxicity Studies For Intravenous Infusions And Injectables

DTAB Recommends To Do Away With Toxicity Studies For Intravenous Infusions And Injectables

Delhi-Gujarat Haul: Drugs Brought From S America, Purified In Ankleshwar

Delhi-Gujarat Haul: Drugs Brought From S America, Purified In Ankleshwar